Logos Global Management LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Logos Global Management LP reported 44 stock positions worth $748.6 million. Its top holding was Ideaya Biosciences (IDYA) at 9.4% of the portfolio, followed by Akero Therapeutics (AKRO, 8.6%) and Revolution Medicines (RVMD, 8.4%). Compared with Q1 2025, it opened 20 new positions, sold out of 14, added to 9 and reduced 9. The biggest buy was a new position in Jazz Pharmaceuticals (JAZZ) and the biggest sale an exit from Nuvalent Class A (NUVL).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $748.6M (Q2 2025)
- SEC Filing
- 0001172661-25-003284 ↗ filed Aug 14, 2025
Holdings Value
Holdings 44 stocks · $748.6M
| IDYA Ideaya Biosciences Inc. | 9.39% | 3,345,000 | $70.3M | Reduce -4.4% |
| AKRO Akero Therapeutics Inc. | 8.55% | 1,200,000 | $64.0M | No change |
| RVMD Revolution Medicines Inc. | 8.35% | 1,700,000 | $62.5M | Add +6.3% |
| JAZZ Jazz Pharmaceuticals PLC | 6.38% | 450,000 | $47.8M | New |
| IRON Disc Medicine Inc. | 4.95% | 700,000 | $37.1M | Add +77.5% |
| RNAM Avidity Biosciences Inc. | 3.60% | 950,000 | $27.0M | Add +171.4% |
| KROS Keros Therapeutics Inc. | 3.57% | 2,000,000 | $26.7M | No change |
| BIIB Biogen Inc. | 3.36% | 200,000 | $25.1M | New |
| UTHR United Therapeutics Corp. | 3.26% | 85,000 | $24.4M | New |
| ARVN Arvinas Inc. | 3.24% | 3,300,000 | $24.3M | New |
| JANX Janux Therapeutics Inc. | 3.09% | 1,000,000 | $23.1M | Reduce -39.4% |
| OCUL Ocular Therapeutix Inc. | 2.73% | 2,200,000 | $20.4M | Reduce -4.3% |
| ERAS Erasca Inc. | 2.54% | 15,000,000 | $19.1M | Add +15.4% |
| NBIX Neurocrine Biosciences Inc. | 2.52% | 150,000 | $18.9M | New |
| DYN Dyne Therapeutics Inc. | 2.42% | 1,900,000 | $18.1M | Add +280.0% |
| IMCR Immunocore Holdings PLC-ADR | 2.41% | 575,000 | $18.0M | New |
| GPCR Structure Therapeutics Inc. | 2.35% | 850,000 | $17.6M | Add +100.0% |
| MDGL Madrigal Pharmaceuticals Inc. | 2.02% | 50,000 | $15.1M | New |
| DSGN Design Therapeutics Inc. | 1.90% | 4,217,627 | $14.2M | No change |
| KRYS Krystal Biotech Inc. | 1.84% | 100,000 | $13.7M | New |
| OLMA Olema Pharmaceuticals Inc. | 1.83% | 3,208,875 | $13.7M | No change |
| CLDX Celldex Therapeutics Inc. | 1.63% | 600,000 | $12.2M | New |
| BHVN Biohaven Ltd. | 1.32% | 700,000 | $9.9M | New |
| XNCR Xencor Inc. | 1.31% | 1,250,000 | $9.8M | New |
| PRAX Praxis Precision Medicines I | 1.26% | 225,000 | $9.5M | New |
| MLTX Moonlake Immunotherapeutics | 1.26% | 200,000 | $9.4M | Reduce -42.9% |
| CDTX Cidara Therapeutics Inc. | 1.24% | 190,000 | $9.3M | New |
| CBIO Crescent Biopharma Inc. | 1.19% | 553,686 | $8.9M | New |
| LEGN Legend Biotech Corp.-ADR | 1.19% | 250,000 | $8.9M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 1.10% | 130,000 | $8.2M | New |
| MAZE Maze Therapeutics Inc. | 1.00% | 611,914 | $7.5M | Reduce -34.7% |
| ELVN Enliven Therapeutics Inc. | 0.94% | 350,000 | $7.0M | Add +45.8% |
| JBIO Jade Biosciences Inc. | 0.83% | 625,000 | $6.2M | New |
| ANNX Annexon Inc. | 0.77% | 2,410,000 | $5.8M | Reduce -39.8% |
| MTSR Metsera Inc. | 0.76% | 200,000 | $5.7M | New |
| TRVI Trevi Therapeutics Inc. | 0.62% | 850,000 | $4.6M | Add +100.1% |
| IMVT Immunovant Inc. | 0.59% | 275,000 | $4.4M | No change |
| VSTM Verastem Inc. | 0.55% | 1,000,000 | $4.2M | New |
| ATXS Astria Therapeutics Inc. | 0.50% | 700,000 | $3.8M | Add +40.0% |
| BCAX Bicara Therapeutics Inc. | 0.50% | 400,000 | $3.7M | New |
| ACRS Aclaris Therapeutics Inc. | 0.35% | 1,850,000 | $2.6M | Reduce -16.8% |
| RAPP Rapport Therapeutics Inc. | 0.32% | 208,910 | $2.4M | No change |
| UNCY Unicycive Therapeutics Inc. | 0.30% | 473,562 | $2.3M | Reduce -6.8% |
| SEPN Septerna Inc. | 0.15% | 109,202 | $1.2M | Reduce -18.6% |
Options reported separately and not counted above: XBI calls ($82.9M), TEVA calls ($25.1M), APLS calls ($17.3M), JANX calls ($11.6M), ARVN calls ($11.0M), LRMR calls ($7.2M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $18K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 66,666 | $18K | No change |
Total filed on the 13F, all lines: $748.6M.
Portfolio Sells Q1 2025 → Q2 2025
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −6.30 |
| JANX Janux Therapeutics Inc. | Reduce -39.4% | 3.09% | −4.83 |
| TEVA Teva Pharmaceutical-SP ADR | Sold out | 0.00% | −4.64 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −3.88 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −3.24 |
| ETNB 89BIO Inc. | Sold out | 0.00% | −3.23 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −3.18 |
| GERN Geron Corp. | Sold out | 0.00% | −2.26 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −2.09 |
| MLTX Moonlake Immunotherapeutics | Reduce -42.9% | 1.26% | −1.17 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −1.02 |
| MAZE Maze Therapeutics Inc. | Reduce -34.7% | 1.00% | −0.83 |
| IDYA Ideaya Biosciences Inc. | Reduce -4.4% | 9.39% | −0.80 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −0.62 |
| ANNX Annexon Inc. | Reduce -39.8% | 0.77% | −0.60 |
| OCUL Ocular Therapeutix Inc. | Reduce -4.3% | 2.73% | −0.27 |
| ACRS Aclaris Therapeutics Inc. | Reduce -16.8% | 0.35% | −0.25 |
| UNCY Unicycive Therapeutics Inc. | Reduce -6.8% | 0.30% | −0.22 |
| GLYCOMIMETICS INC | Sold out | 0.00% | −0.20 |
| ALLK Allakos LLC | Sold out | 0.00% | −0.12 |
| ARTV Artiva Biotherapeutics Inc. | Sold out | 0.00% | −0.08 |
| SLDB Solid Biosciences Inc. | Sold out | 0.00% | −0.07 |
| SEPN Septerna Inc. | Reduce -18.6% | 0.15% | +0.02 |
Portfolio Buys Q1 2025 → Q2 2025
| JAZZ Jazz Pharmaceuticals PLC | New | 6.38% | +6.38 |
| BIIB Biogen Inc. | New | 3.36% | +3.36 |
| UTHR United Therapeutics Corp. | New | 3.26% | +3.26 |
| ARVN Arvinas Inc. | New | 3.24% | +3.24 |
| NBIX Neurocrine Biosciences Inc. | New | 2.52% | +2.52 |
| IMCR Immunocore Holdings PLC-ADR | New | 2.41% | +2.41 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 2.02% | +2.02 |
| KRYS Krystal Biotech Inc. | New | 1.84% | +1.84 |
| RNAM Avidity Biosciences Inc. | Add +171.4% | 3.60% | +1.77 |
| CLDX Celldex Therapeutics Inc. | New | 1.63% | +1.63 |
| DYN Dyne Therapeutics Inc. | Add +280.0% | 2.42% | +1.49 |
| IRON Disc Medicine Inc. | Add +77.5% | 4.95% | +1.47 |
| BHVN Biohaven Ltd. | New | 1.32% | +1.32 |
| XNCR Xencor Inc. | New | 1.31% | +1.31 |
| PRAX Praxis Precision Medicines I | New | 1.26% | +1.26 |
| CDTX Cidara Therapeutics Inc. | New | 1.24% | +1.24 |
| CBIO Crescent Biopharma Inc. | New | 1.19% | +1.19 |
| LEGN Legend Biotech Corp.-ADR | New | 1.19% | +1.19 |
| RYTM Rhythm Pharmaceuticals Inc. | New | 1.10% | +1.10 |
| GPCR Structure Therapeutics Inc. | Add +100.0% | 2.35% | +1.05 |
| JBIO Jade Biosciences Inc. | New | 0.83% | +0.83 |
| MTSR Metsera Inc. | New | 0.76% | +0.76 |
| VSTM Verastem Inc. | New | 0.55% | +0.55 |
| BCAX Bicara Therapeutics Inc. | New | 0.50% | +0.50 |
| TRVI Trevi Therapeutics Inc. | Add +100.1% | 0.62% | +0.15 |
| ELVN Enliven Therapeutics Inc. | Add +45.8% | 0.94% | +0.10 |
| ATXS Astria Therapeutics Inc. | Add +40.0% | 0.50% | +0.03 |
| ERAS Erasca Inc. | Add +15.4% | 2.54% | −0.62 |
| RVMD Revolution Medicines Inc. | Add +6.3% | 8.35% | −1.70 |
Options Activity Q1 2025 → Q2 2025
| XBI SS SPDR S&P Biotech ETF | call | New | 1,000,000 | $82.9M |
| TEVA Teva Pharmaceutical-SP ADR | call | New | 1,500,000 | $25.1M |
| APLS Apellis Pharmaceuticals Inc. | call | New | 1,000,000 | $17.3M |
| JANX Janux Therapeutics Inc. | call | New | 500,000 | $11.6M |
| ARVN Arvinas Inc. | call | New | 1,500,000 | $11.0M |
| LRMR Larimar Therapeutics Inc. | call | New | 2,500,000 | $7.2M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |